HEDS has undertaken work for the TAIN Consortium, a collaborative European research programme whose goal is to create a new, innovative, regulatory approved version of hydrocortisone that can be administered in adrenal insufficiency patients from birth and specifically in the age range 0-6 years.
TAIN was funded by the European Commission through its 7th Framework Programme (Project Number 281654) and was successfully completed on the 30th November 2016 with the submission of a Paediatric Use Market Authorisation (PUMA) application to the European Medicines Agency.
The end of project meeting was held in Berlin on the 25th January 2017 at Charite University of Medicine in the historic Lecture Hall Ruin. Collaborators and speakers at the meeting included representatives from the University of Sheffield, Simcyp Ltd (UK), Charite (Germany), Advanced Drug Delivery Technologies AG (Switzerland), GMBH Glatt (Germany), Diurnal Ltd (UK) and Genetic Alliance UK.
The lead collaborator in Sheffield was Professor Richard Ross, with the economic advice provided by Professor Simon Dixon.